2-(1-ethyl-2-pyrrolidinyl)-ethylamine | 60923-28-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 2-(1-ethyl-2-pyrrolidinyl)-ethylamine
• 英文别名: 2-(aminoethyl)-1-ethylpyrrolidine；2-(aminoethyl)-1-ethyl pyrrolidine；2-(1-ethyl-pyrrolidin-2-yl)-ethylamine；2-(1-Aethyl-pyrrolidin-2-yl)-aethylamin；2-(2-aminoethyl)-1-ethylpyrrolidine；2-aminoethyl-1-ethylpyrrolidine；2-(1-ethylpyrrolidin-2-yl)ethanamine
• CAS: 60923-28-6
• 化学式: C₈H₁₈N₂
• 分子量: 142.244
• InChiKey: SEYURSMOEWBZSA-UHFFFAOYSA-N

物化性质

• 沸点：
  171.8±8.0 °C(Predicted)
• 密度：
  0.896±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(1-ethyl-2-pyrrolidinyl)-ethylamine 在 potassium carbonate 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 26.0h， 生成 [(4S,6S,7R,8S)-11-[2-(1-ethylpyrrolidin-2-yl)ethoxy]-7-methoxy-12-methyl-10,13-dioxo-2,5-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),11-dien-8-yl]methyl carbamate
  参考文献：
  名称：

  Preparation and antitumor activity of additional mitomycin A analogs

  摘要：

  On the basis of qualitative structure-activity relationships developed in the preceding article, a series of 32 new mitomycin A analogues were prepared and tested in antitumor screens. Seven of them gave greater prolongation of life (ILS) than mitomycin C in the mouse P388 leukemia assay. They included examples with 7-O substituents such as cyclic ethers and nitrogen heterocycles. A Hansch analysis was attempted with log P and MR as the independent variables, but no statistically significant correlation could be made. Seven compounds, chosen mainly for their good potency (MED), were tested in the subcutaneous B16 melanoma assay in mice and four of them showed greater ILS than mitomycin C.

  DOI：

  10.1021/jm00123a036
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 sodium hydroxide 、 乙醇 、 镍 作用下， 生成 2-(1-ethyl-2-pyrrolidinyl)-ethylamine
  参考文献：
  名称：

  Paul; Tchelitcheff, Bulletin de la Societe Chimique de France, 1958, p. 736,741

  摘要：

  DOI：

文献信息

• Fused imidazoheterocyclic compounds and pharmaceutical compositions
  申请人：A. H. Robins Company, Inc.

  公开号：US04772600A1

  公开（公告）日：1988-09-20

  Imidazoheterocyclic compounds having the formula: ##STR1## wherein the A ring is pyridine in any of its four positions; B is carbonyl, thioxomethyl or hydroxymethylene; Z is hydrogen, halogen, loweralkyl, hydroxy, loweralkoxy, diloweralkylamino or nitro; Ar is phenyl, pyrido, thienyl or furanyl; and W forms a wide combination of groups with B, including acids, esters, alcohols, amides and ketones. The compounds have CNS activity in a method for treating a living animal body as muscle relaxants, anticonvulsants and antianxiety agents.

  咪唑杂环化合物的化学式为：##STR1## 其中A环是吡啶的四个位置中的任意一个；B是羰基、硫代甲基或羟甲基；Z是氢、卤素、较低烷基、羟基、较低烷氧基、二较低烷基氨基或硝基；Ar是苯基、吡啶基、噻吩基或呋喃基；W与B形成多种组合，包括酸、酯、醇、酰胺和酮。这些化合物在治疗活体动物身体的方法中具有中枢神经系统活性，可用作肌肉松弛剂、抗惊厥剂和抗焦虑剂。
• [EN] FUSED HETEROCYCLIC COMPOUNDS<br/>[FR] COMPOSES HETEROCYCLIQUES CONDENSES
  申请人：TULARIK INC

  公开号：WO2004043958A1

  公开（公告）日：2004-05-27

  Compounds, compositions and methods are provided that are useful in the treatment and/or prevention of a condition or disorder mediated by a G-protein coupled receptor. In particular, the compounds of the invention are useful in the treatment and/or prevention of eating disorders, obesity, anxiety disorders and mood disorders.

  提供了一种在治疗和/或预防由G蛋白偶联受体介导的疾病或紊乱方面有用的化合物、组合物和方法。特别是，本发明的化合物在治疗和/或预防进食紊乱、肥胖、焦虑症和情绪障碍方面是有用的。
• Condensed diazepinones, processes for preparing them and pharmaceutical
  申请人：——

  公开号：US05002943A1

  公开（公告）日：1991-03-26

  Novel condensed diazepinones of general formula I ##STR1## wherein B represents one of the divalent groups ##STR2## and X, A.sup.1, A.sup.2 and R.sup.1 -R.sup.10 are as defined herein. The condensed diazepinones are suitable as vagal pacemakers for the treatment of bradycardia and bradyarrhythmia and they have spasmolytic effects on peripheral organs, particularly the colon, bladder and bronchi.

  新型缩合二氮杂卓酮，其通式为I ##STR1## 其中B代表二价基团之一 ##STR2## 且X、A.sup.1、A.sup.2 和 R.sup.1 -R.sup.10 如本文所定义。这些缩合二氮杂卓酮适用于治疗心动过缓和心搏徐缓性心律失常的迷走神经起搏器，并对周围器官，特别是结肠、膀胱和支气管具有解痉作用。
• [EN] METHODS OF TREATING LIVER DISEASES<br/>[FR] MÉTHODES DE TRAITEMENT DE MALADIES HÉPATIQUES
  申请人：ZAFGEN INC

  公开号：WO2014071368A1

  公开（公告）日：2014-05-08

  The invention provides tricyclic compounds and their use in treating liver disorders, such as non-alcoholic steatohepatitis and related disorders (e.g., fibrosis). The compounds are contemplated to have activity against methionyl aminopeptidase 2.

  这项发明提供了三环化合物及其在治疗肝病方面的用途，如非酒精性脂肪性肝炎和相关疾病（如纤维化）。这些化合物被认为具有对蛋氨酸氨肽酶2的活性。
• Aminoalkylpyrrolidine serotonin receptor ligands and compositions, their pharmaceutical uses, and methods for their synthesis
  申请人：——

  公开号：US20040039044A1

  公开（公告）日：2004-02-26

  Novel aminoalkylpyrrolidine 5-HT 7 receptor ligands, methods of preparing such ligands, intermediate compounds useful in the preparation of the receptor ligands, pharmaceutical compositions comprising the receptor ligands, and methods of treating sleep disorders, pain, depression, and schizophrenia employing the receptor ligands are disclosed. The receptor ligands have formula (1): wherein the formula variables are as defined herein, and pharmaceutically acceptable salts, solvates, active metabolites, or prodrugs thereof.

  揭示了新型氨基烷基吡咯啉5-HT7受体配体，制备这种配体的方法，用于制备受体配体的中间化合物，包括受体配体的药物组合物，以及利用受体配体治疗睡眠障碍、疼痛、抑郁症和精神分裂症的方法。受体配体具有如下式（1）：其中式中的变量如本文所定义，并且包括其药用可接受的盐、溶剂化合物、活性代谢物或前药。